Literature DB >> 9794353

Comparison of alteplase versus heparin for resolution of major pulmonary embolism.

S Konstantinides1, N Tiede, A Geibel, M Olschewski, H Just, W Kasper.   

Abstract

Complete resolution of major pulmonary embolism (PE) treated with heparin alone can often take > 3 weeks. Thrombolytic agents effectively resolve pulmonary artery thrombi within a few hours. However, the effect of the 2 types of treatment on recovery of right ventricular function has not yet been followed for periods of > 24 hours. We prospectively examined 40 consecutive patients with documented major PE (symptoms being present for < or = 8 weeks). After diagnosis, 27 patients (68%) were treated with alteplase plus heparin and 13 (32%) with heparin alone. There was no significant difference between the 2 groups with regard to baseline parameters. At 12 hours, systolic pulmonary artery pressure decreased from 56 +/- 20 to 37 +/- 21 mm Hg in the alteplase group, and from 50 +/- 11 to 46 +/- 12 mm Hg in the heparin group (significantly more; p = 0.016). On echocardiographic follow-up, a decrease in end-diastolic dimensions of the right ventricle and an increase in left ventricular dimensions was significantly more pronounced in the alteplase group (p <0.001 and p = 0.05, respectively). The incidence of right ventricular dilation and paradoxical septal wall motion decreased significantly only in the thrombolyis group. However, at 1-week follow-up, no difference was seen between the 2 groups regarding the overall change in right or left ventricular dimensions or the final values of other echocardiographic parameters. Thus, echocardiography is particularly useful for hemodynamic follow-up of major PE. Thrombolysis may rapidly reduce pulmonary artery pressure, but resolution of right ventricular pressure overload also occurs within 1 week in patients treated with heparin alone.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794353     DOI: 10.1016/s0002-9149(98)00513-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

Review 1.  Tenecteplase to treat pulmonary embolism in the emergency department.

Authors:  Jeffrey A Kline; Jackeline Hernandez-Nino; Alan E Jones
Journal:  J Thromb Thrombolysis       Date:  2007-04       Impact factor: 2.300

2.  Right-to-left interatrial shunt with hypoxemia caused by a right atrial thrombus.

Authors:  Franco Vargas-Beal; Stephanie A Coulter; Sai Yendamuri; Ariadna Contreras; J Michael Duncan
Journal:  Tex Heart Inst J       Date:  2007

Review 3.  [Current status of diagnosis and therapy of acute pulmonary embolism].

Authors:  S Konstantinides
Journal:  Herz       Date:  1999-10       Impact factor: 1.443

4.  The use of thrombolytic therapy in pregnancy.

Authors:  Eric J Gartman
Journal:  Obstet Med       Date:  2013-07-25

Review 5.  [Acute cor pulmonale in pulmonary embolism. An important prognostic factor and a critical parameter for the choice of a therapeutic strategy].

Authors:  S Konstantinides; G Hasenfuss
Journal:  Internist (Berl)       Date:  2004-10       Impact factor: 0.743

6.  Randomized trial of inhaled nitric oxide to treat acute pulmonary embolism: The iNOPE trial.

Authors:  Jeffrey A Kline; Cassandra L Hall; Alan E Jones; Michael A Puskarich; Ronald A Mastouri; Tim Lahm
Journal:  Am Heart J       Date:  2017-01-27       Impact factor: 4.749

7.  Percutaneous catheter-based rheolytic thrombectomy for massive pulmonary embolism: a case report.

Authors:  Dang Nguyen; Yazmin Yaacob; Sobri Muda; Zahiah Mohamed
Journal:  Malays J Med Sci       Date:  2013-03

8.  Acute pulmonary embolus: the next frontier in venous thromboembolic interventions.

Authors:  Tod C Engelhardt
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-09

9.  Pulmonary embolism, part II: Management.

Authors:  Jan Bĕlohlávek; Vladimír Dytrych; Aleš Linhart
Journal:  Exp Clin Cardiol       Date:  2013

10.  Safety of Thrombolysis in a Patient with an Intracranial Dural Arteriovenous Fistula.

Authors:  Ana João Pissarra; Mariana Malheiro; Carolina Gouveia; Patrícia Vicente; Leonor Matos
Journal:  Eur J Case Rep Intern Med       Date:  2019-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.